文献速递银屑病与炎症性皮肤病

血浆细胞外囊泡microRNA作为银屑病患者银屑病关节炎的潜在生物标志物

Circulating microRNAs in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-02-27

本研究探讨血浆来源的细胞外囊泡(EV)microRNA能否作为银屑病患者中银屑病关节炎(PsA)的生物标志物。发现阶段对15例单纯皮肤银屑病(PsC)和14例PsA患者进行RNA测序,验证阶段对29例PsC和28例PsA患者用qPCR分析41个miRNA。结果显示PsA患者血浆EV中let-7b-5p和miR-30e-5p水平显著降低,与PsA存在相关,ROC曲线下面积分别为0.68(95%CI 0.53-0.83)和0.69(95%CI 0.55-0.84)。

要点

  • PsA患者血浆EV中let-7b-5p和miR-30e-5p水平显著低于单纯皮肤银屑病患者。
  • let-7b-5p的AUC为0.68(95%CI 0.53-0.83),miR-30e-5p的AUC为0.69(95%CI 0.55-0.84)。
  • 循环EV microRNA可能作为银屑病患者关节炎的生物标志物。

核心结论

  • 银屑病关节炎患者与单纯皮肤银屑病患者相比,循环EV microRNA水平存在差异。
  • 这项探索性研究提示循环EV microRNA可能作为银屑病患者关节炎的生物标志物。

研究设计与样本

  • 研究纳入单纯皮肤银屑病(PsC)和银屑病合并PsA患者,采集血浆样本。
  • 使用miRCURY™外泌体分离试剂盒分离血浆EV。
  • 发现阶段(PsC n=15;PsA n=14)采用RNA测序鉴定差异表达的EV miRNA。
  • 验证阶段(PsC n=29;PsA n=28)采用qPCR分析41个选定的miRNA。
  • 采用逻辑回归分析评估鉴定出的miRNA与PsA的关联。

主要发现

  • RNA测序在发现队列中鉴定出19个血浆EV miRNA在PsA与PsC之间水平显著不同。
  • 验证队列证实PsA患者血浆EV let-7b-5p和miR-30e-5p水平显著低于PsC患者。
  • let-7b-5p和miR-30e-5p水平降低与PsA的存在相关。
  • ROC分析显示let-7b-5p的AUC为0.68(95% CI 0.53-0.83),miR-30e-5p的AUC为0.69(95% CI 0.55-0.84)。

关键数值与推荐

  • 发现阶段PsC n=15,PsA n=14;验证阶段PsC n=29,PsA n=28。
  • 验证阶段通过qPCR分析41个选定的miRNA。
  • let-7b-5p的ROC AUC为0.68(95% CI 0.53-0.83)。
  • miR-30e-5p的ROC AUC为0.69(95% CI 0.55-0.84)。

临床怎么用

  • 对于银屑病患者,可考虑检测血浆EV let-7b-5p和miR-30e-5p水平以辅助评估PsA风险。
  • 目前这些指标仅作为探索性生物标志物,尚不能替代临床诊断。

局限性

  • 本研究为探索性研究,样本量有限。
  • 研究所鉴定的miRNA作为生物标志物的性能(AUC 0.68和0.69)尚未在独立大样本中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriatic arthritis (PsA) develops in ~30% of patients with psoriasis. The diagnosis of PsA is challenging, and there are no reliable molecular markers in clinical use. MicroRNAs are short non-coding regulatory RNAs, which can be actively packaged into extracellular vesicles (EVs) and secreted to the circulation. OBJECTIVES: To explore whether plasma-derived EV microRNAs may serve as biomarkers for PsA in patients with psoriasis. METHODS: Plasma samples were obtained from patients with cutaneous-only psoriasis (PsC) and patients with psoriasis and PsA. Plasma EVs were isolated using miRCURY™ Exosome Isolation Kit. RNA sequencing was used to identify differentially expressed EV miRNAs in the discovery phase (PsC, n = 15; PsA, n = 14). In the validation phase (PsC, n = 29; PsA, n = 28), 41 selected miRNAs were analysed in plasma EVs by qPCR. The association of the identified miRNAs with PsA was assessed by logistic regression analysis. RESULTS: RNA sequencing identified 19 plasma EV miRNAs with significantly different levels between PsA and PsC in the discovery cohort. Significantly lower levels of plasma EV let-7b-5p and miR-30e-5p in PsA vs. PsC were confirmed in the validation cohort, and their decreased levels were found to be associated with the presence of PsA. ROC analysis revealed an AUC of 0.68 (95% CI 0.53-0.83) for let-7b-5p and 0.69 (95% CI 0.55-0.84) for miR-30e-5p. CONCLUSIONS: Circulating EV microRNA levels are altered in patients with PsA as compared with PsC. Findings of this exploratory study suggest that circulating EV microRNAs may serve as biomarkers for arthritis in psoriasis patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pasquali L, Svedbom A, Srivastava A, et al. Circulating microRNAs in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis. J Eur Acad Dermatol Venereol. 2020. PMID: 31954077. doi:10.1111/jdv.16203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。